专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150204728A1 SPATIAL-DOMAIN LOW-COHERENCE QUANTITATIVE PHASE MICROSCOPY 审中-公开
标题翻译：空域低相位定量相位显微镜
公开(公告)号：US20150204728A1
公开(公告)日：2015-07-23
申请号：US14562092
申请日：2014-12-05
申请人： Yang Liu , Randall E. Brand , Hoa V. Pham , Shikhar Fnu
发明人： Yang Liu , Randall E. Brand , Hoa V. Pham , Shikhar Fnu
IPC分类号： G01J9/02
CPC分类号： G01J9/02 , G01J2009/0223 , G01J2009/0253 , G01J2009/0269 , G01N15/1429 , G01N15/1434 , G01N15/1475 , G01N2015/1402 , G01N2015/1479 , G02B21/14 , G02B21/365
摘要： Systems, methods and other embodiments associated with spatial-domain Low-coherence Quantitative Phase Microscopy (SL-QPM) are described herein. SL-QPM can detect structural alterations within cell nuclei with nanoscale sensitivity (0.9 nm) (or nuclear nano-morphology) for “nano-pathological diagnosis” of cancer. SL-QPM uses original, unmodified cytology and histology specimens prepared with standard clinical protocols and stains. SL-QPM can easily integrate in existing clinical pathology laboratories. Results quantified the spatial distribution of optical path length or refractive index in individual nuclei with nanoscale sensitivity, which could be applied to studying nuclear nano-morphology as cancer progresses. The nuclear nano-morphology derived from SL-QPM offers significant diagnostic value in clinical care and subcellular mechanistic insights for basic and translational research. Techniques that provide for depth selective investigation of nuclear and other cellular features are disclosed.
摘要翻译：本文描述了与空间域低相干定量相位显微镜（SL-QPM）相关联的系统，方法和其它实施例。 SL-QPM可以检测细胞核内的结构变化，具有纳米级灵敏度（0.9 nm）（或核纳米形态），用于癌症的“纳米病理诊断”。 SL-QPM使用原始，未修改的细胞学和组织学标本，用标准临床方案和污渍制备。 SL-QPM可以轻松整合到现有的临床病理实验室。结果量化了具有纳米尺度敏感性的单个核中光程长度或折射率的空间分布，可用于研究核纳米形态作为癌症进展。来自SL-QPM的核纳米形态为临床护理和亚细胞机械学基础和翻译研究提供了显着的诊断价值。公开了提供对核和其他蜂窝特征的深度选择性研究的技术。

2. 发明授权

US11105686B2 Spatial-domain low-coherence quantitative phase microscopy 有权
公开(公告)号：US11105686B2
公开(公告)日：2021-08-31
申请号：US13695230
申请日：2011-05-09
申请人： Yang Liu , Randall E. Brand , Pin Wang , Shikhar Fnu
发明人： Yang Liu , Randall E. Brand , Pin Wang , Shikhar Fnu
IPC分类号： G01J9/02 , G02B21/00 , A61B5/00
摘要： Due to potential sampling errors (due to small tissue samples not necessarily directly from the developing tumor) and limited optical resolution (˜1 micron), cancer may be missed or detected too late for optimal treatment, or conservative interpretation of indeterminate findings could lead to unnecessary surgery. The novel technology herein—Spatial-domain Low-coherence Quantitative Phase Microscopy (SL-QPM)—can detect structural alterations within cell nuclei with nanoscale sensitivity (0.9 nm) (or nuclear nano-morphology) for “nano-pathological diagnosis” of cancer. SL-QPM uses original, unmodified cytology and histology specimens prepared with standard clinical protocols and stains. SL-QPM can easily integrate in existing clinical pathology laboratories. Results quantified the spatial distribution of optical path length or refractive index in individual nuclei with nanoscale sensitivity, which could be applied to studying nuclear nano-morphology as cancer progresses. The nuclear nano-morphology derived from SL-QPM offers significant diagnostic value in clinical care and subcellular mechanistic insights for basic and translational research.

3. 发明申请

US20130229663A1 SPATIAL-DOMAIN LOW-COHERENCE QUANTITATIVE PHASE MICROSCOPY 审中-公开
标题翻译：空域低相位定量相位显微镜
公开(公告)号：US20130229663A1
公开(公告)日：2013-09-05
申请号：US13695230
申请日：2011-05-09
申请人： Liu Yang , Randall E. Brand , Pin Wang , Shikhar Fnu
发明人： Liu Yang , Randall E. Brand , Pin Wang , Shikhar Fnu
IPC分类号： G01J9/02
CPC分类号： G01J9/02 , A61B5/0062 , G02B21/002
摘要： Due to potential sampling errors (due to small tissue samples not necessarily directly from the developing tumor) and limited optical resolution (˜1 micron), cancer may be missed or detected too late for optimal treatment, or conservative interpretation of indeterminate findings could lead to unnecessary surgery. The novel technology herein—Spatial-domain Low-coherence Quantitative Phase Microscopy (SL-QPM)—can detect structural alterations within cell nuclei with nanoscale sensitivity (0.9 nm) (or nuclear nano-morphology) for “nano-pathological diagnosis” of cancer. SL-QPM uses original, unmodified cytology and histology specimens prepared with standard clinical protocols and stains. SL-QPM can easily integrate in existing clinical pathology laboratories. Results quantified the spatial distribution of optical path length or refractive index in individual nuclei with nanoscale sensitivity, which could be applied to studying nuclear nano-morphology as cancer progresses. The nuclear nano-morphology derived from SL-QPM offers significant diagnostic value in clinical care and subcellular mechanistic insights for basic and translational research.
摘要翻译：由于潜在的抽样误差（由于小组织样本不一定直接来自发展中的肿瘤）和有限的光学分辨率（〜1微米），癌症可能被错过或检测到太晚以获得最佳治疗，或者对不确定发现的保守解释可导致不必要的手术。本文的新技术 - 空间域低相干定量相位显微镜（SL-QPM） - 可以检测细胞核内的结构改变，纳米级灵敏度（0.9 nm）（或核纳米形态）用于癌症的“纳米病理诊断” 。 SL-QPM使用原始，未修改的细胞学和组织学标本，用标准临床方案和污渍制备。 SL-QPM可以轻松整合到现有的临床病理实验室。结果量化了具有纳米级灵敏度的单个核中光程长度或折射率的空间分布，可用于研究核纳米形态作为癌症进展。来自SL-QPM的核纳米形态为临床护理和亚细胞机械学基础和翻译研究提供了显着的诊断价值。

4. 发明授权

US06576423B2 Specific mucin expression as a marker for pancreatic cancer 有权
标题翻译：特异性粘蛋白表达作为胰腺癌的标志物
公开(公告)号：US06576423B2
公开(公告)日：2003-06-10
申请号：US09733444
申请日：2000-12-08
申请人： Surinder K. Batra , Randall E. Brand , Jöerg Ringel , Grit Faulmann , Matthias Löhr , Grish C. Varshney
发明人： Surinder K. Batra , Randall E. Brand , Jöerg Ringel , Grit Faulmann , Matthias Löhr , Grish C. Varshney
IPC分类号： C12Q168
CPC分类号： C07K16/303 , C07K16/3092 , C12Q1/6886 , C12Q2600/158 , G01N33/57438 , G01N2333/4725
摘要： Methods are provided for the diagnosis of pancreatic cancer.
摘要翻译：为诊断胰腺癌提供了方法。

5. 发明申请

US20110257029A1 BIOMARKERS FOR PANCREATIC CANCER AND DIAGNOSTIC METHODS 有权
标题翻译：胰腺癌生物标志物和诊断方法
公开(公告)号：US20110257029A1
公开(公告)日：2011-10-20
申请号：US12951718
申请日：2010-11-22
申请人： Brian B. Haab , Tingting Yue , Randall E. Brand
发明人： Brian B. Haab , Tingting Yue , Randall E. Brand
IPC分类号： C40B30/04 , C40B40/10 , G01N33/577
CPC分类号： G01N33/5308 , G01N33/57438 , G01N33/6803
摘要： Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.
摘要翻译：用于区分胰腺癌与良性胰腺疾病的方法和相关试剂盒。该方法包括测定患者生物样品中CA19-9抗原的总水平和特异性粘蛋白中的聚糖水平，并比较CA 19-9抗原的总水平和特异性粘蛋白中的聚糖水平（ s）到统计学验证的阈值，其中与统计学验证的阈值相比，与统计学验证的阈值和特定粘蛋白中的不同水平的聚糖水平相比，患者生物样品中总CA 19-9抗原的不同水平指示患者的胰腺癌，而不是良性胰腺疾病。

6. 发明授权

US08632983B2 Biomarkers for pancreatic cancer and diagnostic methods 有权
标题翻译：胰腺癌生物标志物和诊断方法
公开(公告)号：US08632983B2
公开(公告)日：2014-01-21
申请号：US12951718
申请日：2010-11-22
申请人： Brian B. Haab , Tingting Yue , Randall E. Brand
发明人： Brian B. Haab , Tingting Yue , Randall E. Brand
IPC分类号： G01N33/53 , C12Q1/00
CPC分类号： G01N33/5308 , G01N33/57438 , G01N33/6803
摘要： Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.
摘要翻译：用于区分胰腺癌与良性胰腺疾病的方法和相关试剂盒。该方法包括测定患者生物样品中CA19-9抗原的总水平和特异性粘蛋白中的聚糖水平，并比较CA 19-9抗原的总水平和特异性粘蛋白中的聚糖水平（ s）到统计学验证的阈值，其中与统计学验证的阈值相比，与统计学验证的阈值和特定粘蛋白中的不同水平的聚糖水平相比，患者生物样品中总CA 19-9抗原的不同水平指示患者的胰腺癌，而不是良性胰腺疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式